Michael Retsky (Ph.D. in physics from University of Chicago) made a career change from physics to cancer research. He is Editor-in-Chief of Journal of Bioavailability and Bioequivalence, on staff at Harvard School of Public Health, faculty at University College London, and Prof Adj at UANL, Monterrey, Mexico. He was on Judah Folkman’s staff at Harvard Medical School for 12 years. He is on the board of directors of the Colon Cancer Alliance and has published more than 60 papers in physics and cancer. He has a patent pending for treatment of early stage cancer. Michael Retsky (Ph.D. in physics from University of Chicago) made a career change from physics to cancer research. He is Editor-in-Chief of Journal of Bioavailability and Bioequivalence, on staff at Harvard School of Public Health, faculty at University College London, and Prof Adj at UANL, Monterrey, Mexico. He was on Judah Folkman’s staff at Harvard Medical School for 12 years. He is on the board of directors of the Colon Cancer Alliance and has published more than 60 papers in physics and cancer. He has a patent pending for treatment of early stage cancer.

Smart Drug Delivery Technology Nano medicine and Drug Delivery Drug targeting Drug Design and Drug Formulation Anti-Cancer Drug Discovery